Cargando…
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
BACKGROUND: Clinical targeting of TNFR family of receptors (CD40, CD134 and CD137) with immunostimulatory monoclonal antibodies has been successful in cancer immunotherapy. However, targeting of CD27 with a mAb is a relatively new approach to provide costimulation of immune cells undergoing activati...
Autores principales: | Ramakrishna, Venky, Sundarapandiyan, Karuna, Zhao, Biwei, Bylesjo, Max, Marsh, Henry C., Keler, Tibor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619281/ https://www.ncbi.nlm.nih.gov/pubmed/26500773 http://dx.doi.org/10.1186/s40425-015-0080-2 |
Ejemplares similares
-
Immune correlates of Varlilumab treated cancer patients are consistent with CD27 costimulatory activity
por: Bullock, Timothy, et al.
Publicado: (2014) -
The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent
por: He, Li-Zhen, et al.
Publicado: (2015) -
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
por: Sanborn, Rachel E, et al.
Publicado: (2022) -
Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy
por: Vitale, Laura A., et al.
Publicado: (2020) -
Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
por: Thomas, Lawrence J, et al.
Publicado: (2014)